SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Ask DrBob
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dr. B. ® who wrote (61527)6/13/2002 4:31:23 PM
From: stan_hughes   of 100058
 
dr_b - Temporary BGEN drop an over-reaction to the following:

4:17pm 06/13/02

Shares of Biogen dropped 6 percent in after-hours trading Thursday after the U.S. Food and Drug Administration asked for additional data and "clarification" about the biotech firm's experimental treatment for psoriasis. Biogen also said the FDA had proposed post-marketing studies to "further define the safety and effectiveness" of the drug, Amevive. Such requests from the FDA for additional information can delay the approval of a drug. Shares of Biogen (BGEN) fell $2.44 to $37 in recent after-hours action.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News